Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ

$26.86

-$0.41 (1.52%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$26.52$27.95

Open $27.60

52 Week Range

$22.24$46.00

Previous Close $27.27

Market Cap1.57B

Volume931.96K

Avg Volume1.23M

P/E (TTM)-3.89

EPS (TTM)$-6.90

Dividend / YieldN/A

Dividend StreakN/A

Insider Trading Summary(Q4 2025)

Total Transactions

5 buys /10 sells

Shares Acquired

6,356

Transactions: 5•Avg: 1,271.2

Shares Disposed

12,712

Transactions: 10•Avg: 1,271.2

Net Activity

-6,356

Net Selling•Ratio: 50%

Quarterly Insider Trading Summary


Q4 2025(Current)	6,356	12,712	-6,356	50.00%
Q3 2025	84,589	97,942	-13,353	61.11%
Q2 2025	247,841	135,579	+112,262	137.50%
Q1 2025	612,853	119,427	+493,426	100.00%
Q4 2024	10,200	62,924	-52,724	16.67%

Showing 1 to 5 of 48 entries

This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.

Market Transactions

Stock Purchases

Acquired Shares:6,356

Transactions:5

Avg per Transaction:1,271.2

Insider acquisitions during this period

Stock Sales

Disposed Shares:12,712

Transactions:10

Avg per Transaction:1,271.2

Insider dispositions during this period

Buy/Sell Ratio:50%

More shares disposed than acquired in this period

• Most recent data for Q4 2025

Insider Buy/Sell Activity

Quarterly Transaction Count

Q4 2025

5/10

Q3 2025

11/18

Q2 2025

33/24

Q1 2025

32/32

Acquired

Disposed

Quarterly Share Volume

Q4 2025

Net Activity by Quarter

Values in thousands of shares

+355k

Q1 2024

+100k

Q2 2024

-17k

Q3 2024

-53k

Q4 2024

+493k

Q1 2025

+112k

Q2 2025

-13k

Q3 2025

-6k

Q4 2025

Buy/Sell Ratio

50%

Bearish signal

Activity Trend

Increasing

Based on 48 quarters of data

Current Net Activity

-6,356 shares

$5 value

Acquired vs Disposed Shares

Net Distribution: 6,356 shares•Acquired/Disposed Ratio: 50%

Top Insider Activity

					Net Activity
FJA FOUSE JACQUALYN A	Director	5	36,637	2,120	+34,517
GB Goff Brian	Director, officer: chief executive officer	9	60,968	90,753	-29,785
BJT Backstrom Jay T.	Director	3	27,734	0	+27,734
GS Gheuens Sarah	Officer: chief medical officer	19	32,244	57,114	-24,870
CJD CAPELLO JEFFREY D	Director	6	22,726	4,097	+18,629

Showing 1 to 5 of 5 entries

This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.

Recent Insider Transactions


2025-11-12	Scadden David	Director	Sale	200	$18.09	$3,618	26,907
2025-11-12	Scadden David	Director	Purchase	200	$18.09	$3,618	17,803
2025-11-12	Scadden David	Director	Sale	200	$43.84	$8,768	17,603
2025-11-11	Gheuens Sarah	Officer: chief medical officer	Purchase	2,454	$25.01	$61,374.54	64,181
2025-11-11	Gheuens Sarah	Officer: chief medical officer	Sale	2,454	$43.78	$107,436.12	61,727

Showing 1 to 5 of 100 entries

This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.

Recent SEC Filings


SD Scadden David	Director	Nov 14, 2025	View Filing
SD Scadden David	Director	Nov 14, 2025	View Filing
SD Scadden David	Director	Nov 14, 2025	View Filing
GS Gheuens Sarah	Officer: chief medical officer	Nov 13, 2025	View Filing
GS Gheuens Sarah	Officer: chief medical officer	Nov 13, 2025	View Filing

Showing 1 to 5 of 5 entries

Insider Trading Summary(Q4 2025)

Total Transactions

5 buys /10 sells

Shares Acquired

6,356

Transactions: 5•Avg: 1,271.2

Shares Disposed

12,712

Transactions: 10•Avg: 1,271.2

Net Activity

-6,356

Net Selling•Ratio: 50%

Quarterly Insider Trading Summary


Q4 2025(Current)	6,356	12,712	-6,356	50.00%
Q3 2025	84,589	97,942	-13,353	61.11%
Q2 2025	247,841	135,579	+112,262	137.50%
Q1 2025	612,853	119,427	+493,426	100.00%
Q4 2024	10,200	62,924	-52,724	16.67%

Showing 1 to 5 of 48 entries

This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.

Market Transactions

Stock Purchases

Acquired Shares:6,356

Transactions:5

Avg per Transaction:1,271.2

Insider acquisitions during this period

Stock Sales

Disposed Shares:12,712

Transactions:10

Avg per Transaction:1,271.2

Insider dispositions during this period

Buy/Sell Ratio:50%

More shares disposed than acquired in this period

• Most recent data for Q4 2025

Insider Buy/Sell Activity

Quarterly Transaction Count

Q4 2025

5/10

Q3 2025

11/18

Q2 2025

33/24

Q1 2025

32/32

Acquired

Disposed

Quarterly Share Volume

Q4 2025

Net Activity by Quarter

Values in thousands of shares

+355k

Q1 2024

+100k

Q2 2024

-17k

Q3 2024

-53k

Q4 2024

+493k

Q1 2025

+112k

Q2 2025

-13k

Q3 2025

-6k

Q4 2025

Buy/Sell Ratio

50%

Bearish signal

Activity Trend

Increasing

Based on 48 quarters of data

Current Net Activity

-6,356 shares

$5 value

Acquired vs Disposed Shares

Net Distribution: 6,356 shares•Acquired/Disposed Ratio: 50%

Top Insider Activity

					Net Activity
FJA FOUSE JACQUALYN A	Director	5	36,637	2,120	+34,517
GB Goff Brian	Director, officer: chief executive officer	9	60,968	90,753	-29,785
BJT Backstrom Jay T.	Director	3	27,734	0	+27,734
GS Gheuens Sarah	Officer: chief medical officer	19	32,244	57,114	-24,870
CJD CAPELLO JEFFREY D	Director	6	22,726	4,097	+18,629

Showing 1 to 5 of 5 entries

This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.

Recent Insider Transactions


2025-11-12	Scadden David	Director	Sale	200	$18.09	$3,618	26,907
2025-11-12	Scadden David	Director	Purchase	200	$18.09	$3,618	17,803
2025-11-12	Scadden David	Director	Sale	200	$43.84	$8,768	17,603
2025-11-11	Gheuens Sarah	Officer: chief medical officer	Purchase	2,454	$25.01	$61,374.54	64,181
2025-11-11	Gheuens Sarah	Officer: chief medical officer	Sale	2,454	$43.78	$107,436.12	61,727

Showing 1 to 5 of 100 entries

This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.

Recent SEC Filings


SD Scadden David	Director	Nov 14, 2025	View Filing
SD Scadden David	Director	Nov 14, 2025	View Filing
SD Scadden David	Director	Nov 14, 2025	View Filing
GS Gheuens Sarah	Officer: chief medical officer	Nov 13, 2025	View Filing
GS Gheuens Sarah	Officer: chief medical officer	Nov 13, 2025	View Filing

Showing 1 to 5 of 5 entries